Does IPILIMUMAB Cause Interstitial lung disease? 487 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 487 reports of Interstitial lung disease have been filed in association with IPILIMUMAB (YERVOY). This represents 1.3% of all adverse event reports for IPILIMUMAB.
487
Reports of Interstitial lung disease with IPILIMUMAB
1.3%
of all IPILIMUMAB reports
123
Deaths
303
Hospitalizations
How Dangerous Is Interstitial lung disease From IPILIMUMAB?
Of the 487 reports, 123 (25.3%) resulted in death, 303 (62.2%) required hospitalization, and 65 (13.3%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for IPILIMUMAB.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Malignant neoplasm progression (3,296)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which IPILIMUMAB Alternatives Have Lower Interstitial lung disease Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN